

RSV VACCINATION IN PREGNANCY

Pregnancy EGA 32w0d - 36w6d
 No anaphylaxis to vaccine component
 Current timing: Sept 1 through January 31 (not EDC)

Yes all

No to any

Recommend maternal vaccination

No vaccination or defer maternal vaccination until EGA or in season

Single dose Pfizer's bivalent RSVpreF vaccine (Abrysvo) IM (deltoid)*

Consider neonatal or infant RSV nirsevimab
 One dose of nirsevimab is recommended for infants younger than 8 months of age who were born shortly before or are entering their first RSV season (typically fall through spring) if

- The mother did not receive RSV vaccine during pregnancy.
- The mother's RSV vaccination status is unknown.
- The infant was born within 14 days of maternal RSV vaccination.

nirsevimab is not needed for most infants younger than age 8 months who are born 14 or more days after their mother received RSV vaccine

• Pregnant people can receive RSV, Tdap, COVID-19, and influenza vaccines at the same clinic visit when the vaccines are recommended

RSVpreF (Abrysvo, Pfizer): recombinant RSV F protein antigen (both the RSV-A and RSV-B subtypes). Single-dose vial of 120 µg of lyophilized preF antigen component (60 µg from RSV-A, 60 µg from RSV-B)

2 RCTS'S -3700 pregnant patients
 Vaccine:

- reduced risk of RSV hospitalization by 68% (3 months, 57% (6 months)
- reduced risk of RSV office visit by 57% and 51% (3 and 6 months)
- reduced the risk of severe RSV disease by 82% within 3 months and by 69% within 6 months after birth

Reported side effects: pain at the injection site, headache, myalgia, and nausea
 Adverse events:

- PTB: 4.2% of pregnant people who received the RSV vaccine; 3.7% of pregnant people who received a placebo
- HTN disease of pregnancy: 1.8% of pregnant people who received the RSV vaccine compared to 1.4% of pregnant people who received a placebo

Food and Drug Administration: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Press Release. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administrations; 2023.
<https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants>

Food and Drug Administration. ABRYSVO package insert. Silver Springs, MD: US Department of Health and Human Services, Food and Drug Administrations; 2023. <https://www.fda.gov/media/168889/download?attachment>

Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20; 388(1):1451-1464. doi:10.1056/NEJMoa2216480.

Hamid S, Winn A, Parikh R, et al. Seasonality of Respiratory Syncytial Virus – United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023 Apr 7;72(14):355-361. doi: 10.15585/mmwr.mm7214a1

CDC RSV Surveillance & Research

These algorithms are designed to assist the primary care provider in the clinical management of a variety of problems that occur during pregnancy. They should not be interpreted as a standard of care, but instead represent guidelines for management. Variation in practices should take into account such factors as characteristics of the individual patient, health resources, and regional experience with diagnostic and therapeutic modalities. The algorithms remain the intellectual property of the University of North Carolina at Chapel Hill School of Medicine. They cannot be reproduced in whole or in part without the expressed written permission of the school. www.mombaby.org
 Created 1/8/24 BG/JJ